Histotripsy(组织碎化技术)

Search documents
长和上千亿港口交易暂停后,李嘉诚首次露面
Sou Hu Cai Jing· 2025-04-04 07:17
Group 1: Company Overview - CK Hutchison Holdings Limited (长江和记实业有限公司) has not publicly responded following the missed signing date for the port transaction originally set for April 2 [1] - The company announced on March 4 its intention to sell a series of port operations, including those at the Panama Canal, to a consortium led by BlackRock for a total price of $22.765 billion [1][6] - The port division of CK Hutchison operates 293 berths across 53 ports in 24 countries, handling a total throughput of 82.1 million TEUs in 2023 [6] Group 2: Market Reaction - Following the announcement of the port transaction, BlackRock's stock price fell by 8.16% from March 4 to April 3 [2] - CK Hutchison's stock price also declined by 14.94% during the same period, transitioning from an upward trend to a downward one [2] Group 3: Regulatory Scrutiny - The Chinese National Market Supervision Administration announced it would review the port transaction to ensure fair market competition and protect public interests [8][9] - Reports indicated that CK Hutchison and BlackRock would not sign any agreements during the week of March 31 to April 6, as they sought a reasonable solution in communication with the Hong Kong government [9] Group 4: Technological Developments - On April 3, Li Ka-shing publicly endorsed the Histotripsy technology for cancer treatment, which is being introduced in Singapore through a collaboration with Temasek [3][4] - The technology has shown significant results in Hong Kong, with 50 liver cancer patients successfully treated since its introduction [4]
李嘉诚视频“现身”
证券时报· 2025-04-03 13:31
Core Viewpoint - The collaboration between Li Ka-shing Foundation and Temasek Trust to introduce Histotripsy technology for cancer treatment in Singapore is a significant advancement in medical innovation aimed at improving patient outcomes [1][2]. Group 1: Introduction of Histotripsy Technology - Histotripsy, a non-invasive ultrasound technology for tumor treatment, is being introduced to two hospitals in Singapore [1]. - The technology aims to provide hope and reduce pain for cancer patients, allowing for quicker recovery [2]. Group 2: Li Ka-shing's Involvement - Li Ka-shing expressed his honor in collaborating with Temasek Trust and emphasized the importance of medical innovation in combating cancer [2]. - He described Histotripsy as "incredible" and highlighted its potential to shatter cancer cells without radiation or ablation [2]. Group 3: Future Prospects - Since the arrival of the first machine in Hong Kong in September 2024, 50 liver cancer patients have successfully undergone treatment [2]. - Li Ka-shing anticipates that the development of this technology will benefit patients in Singapore and beyond [2].